Angel R. Nebreda

    <p>Angel R Nebreda</p>
    Research Group: 
    Signalling and Cell Cycle Laboratory
    Unit: 
    ONCOLOGY
    Position: 
    Group Leader
    Office: 
    EM01B53-4-C53
    Telephone: 
    +34 93 40 31379
    Email: 
    angel.nebreda@irbbarcelona.org

    ICREA Research Professor, ERC Advanced Grant

     

    View research group

    Dr. Angel R. Nebreda obtained his Degree in Biology at Universidad de Salamanca in 1982 and a PhD in Molecular Biology from the same university in 1986. He then worked as postdoc at the National Institutes of Health (NIH) in Bethesda (USA) and the Cancer Research-UK Clare Hall Laboratories in South Mimms (UK). In 1995, he started his own group at the European Molecular Biology Laboratory (EMBL) in Heidelberg (Germany) where he worked for 9 years and then moved to the newly created Spanish National Cancer Research Center (CNIO) in Madrid (Spain) as a Senior Group Leader.

    From 2010 Dr. Nebreda is an ICREA Research Professor and Group Leader at the IRB Barcelona. His research interests focus on signal transduction mechanisms (MAPKs, CDKs) in cell proliferation, differentiation and survival, particularly in relation to cancer. He was elected EMBO member in 2003. During his career, he occupied different positions as Scientific Advisor in cancer and related areas for companies such as Eli Lilly and funding organizations such as AICR, EMBO, ERC, CNRS, as well as as editor of FEBS letters and the Biochemical Journal.

    Selected group publications

    Induction of oxidative metabolism by the p38α/MK2 pathway
    Trempolec N, Muñoz JP, Slobodnyuk K, Marin S, Cascante M, Zorzano A and Nebreda AR.
    Sci Rep, 7 (1), 11367 (2017)
    Essential role of the Cdk2 activator RingoA in meiotic telomere tethering to the nuclear envelope
    Mikolcevic P, Isoda M, Shibuya H, del Barco Barrantes I, Igea A, Suja JA, Shackleton S, Watanabe Y and Nebreda AR.
    Nat Commun, 7 11084 (2016)
    Gene Dosage Imbalance Contributes to Chromosomal Instability-Induced Tumorigenesis
    Clemente-Ruiz M, Murillo-Maldonado JM, Benhra N, Barrio L, Pérez L, Quiroga G, Nebreda AR and Milán M.
    Dev Cell, 36 (3), 290-302 (2016)
    The Stress Kinase p38α as a Target for Cancer Therapy
    Igea A and Nebreda AR.
    Cancer Res, 75 (19), 3997-4002 (2015)
    Dual function of p38α MAPK in colon cancer: suppression of colitis-associated tumor initiation but requirement for cancer cell survival
    Gupta J, del Barco Barrantes I, Igea A, Sakellariou S, Pateras IS, Gorgoulis VG and Nebreda AR.
    Cancer Cell, 25 (4), 484-500 (2014)
    Colon cancer cells colonize the lung from established liver metastases through p38 MAPK signalling and PTHLH
    Urosevic J, Garcia-Albéniz X, Planet E, Real S, Céspedes MV, Guiu M, Fernandez E, Bellmunt A, Gawrzak S, Pavlovic M, Mangues R, Dolado I, Barriga FM, Nadal C, Kemeny N, Batlle E, Nebreda AR and Gomis RR.
    Nat Cell Biol, 16 (7), 685-94 (2014)
    Inhibition of p38 MAPK sensitizes tumour cells to cisplatin-induced apoptosis mediated by reactive oxygen species and JNK
    Pereira L, Igea A, Canovas B, Dolado I and Nebreda AR.
    EMBO Mol Med, 5 (11), 1759-1774 (2013)
    SnapShot: p38 MAPK signaling
    Trempolec N, Dave-Coll N and Nebreda AR.
    Cell, 152 (3), 656-657 (2013)
    SnapShot: p38 MAPK substrates
    Trempolec N, Dave-Coll N and Nebreda AR.
    Cell, 152 (4), 924-925 (2013)
    Genetic analysis of specific and redundant roles for p38alpha and p38beta MAPKs during mouse development
    del Barco Barrantes I, Coya JM, Maina F, Arthur JS and Nebreda AR.
    P Natl Acad Sci Usa, 108 (31), 12764-9 (2011)
    Mechanisms and functions of p38 MAPK signalling
    Cuadrado A and Nebreda AR.
    Biochem J, 429 (3), 403-17 (2010)
    Full publication list